Netherlands

The Netherlands has solidified its position as a European life sciences powerhouse, serving as the operational heart for the European Medicines Agency (EMA) and a magnet for foreign direct investment.

Best known for its highly collaborative "triple helix" model, the Dutch ecosystem seamlessly integrates academic research excellence, government support and private sector innovation.

The country is a global leader in biotechnology, particularly within the fields of oncology, cell and gene therapy and immunology, anchored by the world-renowned Leiden Bio Science Park.

In the pharmaceutical sector, the Netherlands acts as a critical logistical gateway for global drug distribution and a premier location for Phase I-III clinical trials.

The Dutch medical device (medtech) industry is equally robust, driving advancements in imaging technology, wearable health tech and AI-driven diagnostics.

Beyond traditional manufacturing, the region excels in healthcare innovation, prioritizing digital health solutions and personalized medicine to improve patient outcomes.

With eight elite University Medical Centers (UMCs) and a dense network of over 3,000 R&D companies, the Netherlands offers an unparalleled environment for translational research and open innovation.

From pioneering Organ-on-a-Chip technologies to sustainable biopharmaceutical manufacturing, the Dutch life sciences sector continues to define the future of global health.